AptarGroup (NYSE:ATR) announced today that it received FDA approval for its nasal pump to deliver a pharmaceutical treatment for dry eye. Crystal Lake, Illinois–based Aptar said the patented Cartridge Pump System (CPS) is for the multidose delivery of preserved and non-preserved drug formulations. It has received approval as the device for delivering Oyster Point Pharma’s […]
oysterpointpharma
Oyster Point raises $93m for intranasal dry eye disease therapies
Oyster Point Pharma said yesterday that it raised $93 million in a Series B round to support the clinical development of its intranasal dry eye disease therapies. The Princeton, N.J.-based company’s lead product candidates for dry eye disease are designed to stimulate the trigeminal parasympathetic pathway to trigger natural tear film production. The drugs, OC-01 and […]
Oyster Point Pharma touts trial results for intranasal dry eye disease drugs
Oyster Point Pharma touted data today from two Phase IIb trials assessing its nasal spray products for the treatment of dry eye disease. Both studies showed that use of OC-01 and OC-02 led to improvements in multiple measures of eye dryness symptoms, according to the Princeton, N.J.-based company. Oyster Point’s Onset study evaluated the safety […]
Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique
Large pharmaceutical companies dominate the dry eye disease space – Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops. Eight-person Oyster Point Pharma wants in on that market. But it’s betting on a completely different approach. “What we’ve come up with is a very innovative nasal spray, which when […]
